Dr. Ayad Abdul-Ahad This is Me

Education

 View all 6 references Web References

1. 1. Boston Cure Project - People

   www.bostoncure.com/about/peopl - [Cached]

   Published on: 3/1/2004   Last Visited: 3/1/2004

   Ayad Abdul-Ahad, M.B., Ch.B., M.Sc., Ph.D., FRCPath
   ...
   Ayad Abdul-Ahad, M.B., Ch.B., M.Sc., Ph.D., FRCPath Pharmaceutical Advisory Board
   
   Ayad Abdul-Ahad, M.B., Ch.B., M.Sc., Ph.D., FRCPath
   ...
   Ayad Abdul-Ahad is the Vice President of CNS Clinical Development at Berlex Laboratories Inc., Montville, New Jersey. During the last 10 years, he has held a variety of positions in the pharmaceutical industry in the US, UK, Switzerland and Belgium. He was responsible for designing and executing the clinical development programs of Rebif in multiple sclerosis while working with Serono in Switzerland. Also he has directed the clinical development of other biotechnology drugs in oncology, virology and hematology. Dr. Abdul-Ahad obtained his medical degree from Baghdad University. He specialized in immuno-oncology in the United Kingdom, obtaining a PhD from Southhampton University, an MSc from London University as well as the Membership, then Fellowship of the Royal College of Pathologists in Immunology.

2. 2. www.mult-sclerosis.org

   www.mult-sclerosis.org/news/Ap - [Cached]

   Published on: 4/19/2002   Last Visited: 12/10/2007

   "The philosophy of the new study is really to see if the drug can offer more benefits to the patients by going to the higher dose," says Dr. Ayad Abdulahad, vice president of clinical development for central nervous system at Berlex, which is in Montville, N.J.
   
   He says previous research and studies indicate the higher dose is more effective than the current approved dose. They'll attempt to confirm that with this large-scale trial, which is being done in response to the needs of people with MS and at the urging of MS specialists, Abdulahad says.
   
   While the current 250-mcg dose is effective, "we expect the 500-microgram dose to deliver more benefit to the patient," he says.
   ...
   Interferon beta-1b helps reduce inflammation that MS causes in the central nervous system, Abdulahad says.

3. 3. Healthtalk / Healthscout News

   www.healthtalkinteractive.com/ - [Cached]

   Published on: 4/1/2002   Last Visited: 11/29/2002

   "The philosophy of the new study is really to see if the drug can offer more benefits to the patients by going to the higher dose," says Dr. Ayad Abdulahad, vice president of clinical development for central nervous system at Berlex, which is in Montville, N.J.
   
   He says previous research and studies indicate the higher dose is more effective than the current approved dose. They'll attempt to confirm that with this large-scale trial, which is being done in response to the needs of people with MS and at the urging of MS specialists, Abdulahad says.
   
   While the current 250-mcg dose is effective, "we expect the 500-microgram dose to deliver more benefit to the patient," he says.
   
   Relapsing-remitting MS is the most common form of the disease. It's characterized by partial or total recovery after attacks that may include vision problems or movement disorders. About 70 percent of people with MS initially have the relapsing-remitting form.
   
   MS is a chronic disease that involves inflammation and the breakdown of the protective insulation, called a myelin sheath, that surrounds the nerve fibers of the central nervous system, says the National Multiple Sclerosis Society.
   
   ...
   Interferon beta-1b helps reduce inflammation that MS causes in the central nervous system, Abdulahad says.
   
   It's too soon to comment on the importance or potential impact of this trial, says Arney Rosenblat, public affairs director for the National Multiple Sclerosis Society.
   
   "But any study of this size will surely add to the overall body of knowledge about treating MS and that should be encouraged," she says.
   
   She says there are several different drugs available to treat MS symptoms.
   
   "But all of the products do basically the same thing -- they reduce the number of attacks and the severity of the attacks by about a third. And indications are that they slow disease progression," Rosenblat says.
   
   She says some people respond better to one drug than to another.
   
   If this trial into a higher dose of interferon beta-1b is successful, it will give people with MS another option for managing their disease, Rosenblat says.
   ...
   SOURCES: Ayad Abdulahad, M.D., Ph.D., vice president of clinical development for the central nervous system, Berlex Laboratories, Montville, N.J.; Arney Rosenblat, public affairs director, National Multiple Sclerosis Society, New York Copyright © 2002 ScoutNews, LLC. All rights reserved. This is a story from HealthScoutNews, a service of ScoutNews, LLC.